The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Open accessAbstract
Cyclic guanosine monophosphate (cGMP) is a second messenger molecule that transduces nitric-oxide- and natriuretic-peptide-coupled signalling, stimulating phosphorylation changes by protein kinase G. Enhancing cGMP synthesis or blocking its degradation by phosphodiesterase type 5A (PDE5A) protects against cardiovascular disease. However, cGMP stimulation alone is limited by counter-adaptions including PDE upregulation. Furthermore, although PDE5A regulates nitric-oxide-generated cGMP, nitric oxide signalling is often depressed by heart disease. PDEs controlling natriuretic-peptide-coupled cGMP remain uncertain. Here we show that cGMP-selective PDE9A (refs 7, 8) is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure. PDE9A regulates natriuretic-peptide- rather than nitric-oxide-stimulated cGMP in heart myocytes and muscle, and its genetic or selective pharmacological inhibition protects against pathological responses to neurohormones, and sustained pressure-overload stress. PDE9A inhibition reverses pre-established heart disease independent of nitric oxide synthase (NOS) activity, whereas PDE5A inhibition requires active NOS. Transcription factor activation and phosphoproteome analyses of myocytes with each PDE selectively inhibited reveals substantial differential targeting, with phosphorylation changes from PDE5A inhibition being more sensitive to NOS activation. Thus, unlike PDE5A, PDE9A can regulate cGMP signalling independent of the nitric oxide pathway, and its role in stress-induced heart disease suggests potential as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many technological developments have been prominent, including phospho-PTM analysis to identify PDE5A targets in heart failure therapy118”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [118]
In the citing paper
“Now, identification of proteoforms (e.g., genetic variations, alternatively spliced products, phosphorylation118, glycosylation119, oxidative120 and other PTMs121) allow CVD sub-classification.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Conti, M., & Beavo, J. A. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.150444 · Cited by 1,219
Redfield, M. M., Chen, H. H., Borlaug, B. A., Semigran, M. J., Lee, K. L., Lewis, G. D., LeWinter, M. M., Rouleau, J. L., Bull, D. A., Mann, D. L., et al. (2013) · JAMA · doi:10.1001/jama.2013.2024 · Cited by 1,164
Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart
Zhou, B., Ma, Q., Rajagopal, S., Wu, S. M., Domian, I., Rivera-Feliciano, J., Jiang, D., von Gise, A., Ikeda, S., Chien, K. R., et al. (2008) · Nature · doi:10.1038/nature07060 · Cited by 1,019
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D. F., Ren, S. V., Rodríguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 902
Self-citationAdvances in targeting cyclic nucleotide phosphodiesterases
Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J. H., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 824
Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction
van Heerebeek, L., Hamdani, N., Falcão‐Pires, I., Leite-Moreira, A. F., Begieneman, M. P. V., Bronzwaer, J. G. F., van der Velden, J., Stienen, G. J. M., Laarman, G. J., Somsen, G. A., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.076075 · Cited by 545
Self-citationHeart Failure With Preserved Ejection Fraction: Mechanisms, Clinical Features, and Therapies
Sharma, K., & Kass, D. A. (2014) · Circulation Research · doi:10.1161/circresaha.115.302922 · Cited by 508
Self-citationOka, T., Maillet, M., Watt, A. J., Schwartz, R. J., Aronow, B. J., Duncan, S. A., & Molkentin, J. D. (2006) · Circulation Research · doi:10.1161/01.res.0000215985.18538.c4 · Cited by 424
A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo
Davis, J., Burr, A. R., Davis, G. F., Birnbaumer, L., & Molkentin, J. D. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.08.017 · Cited by 362
Cited by
Sorted by citations
Mechanisms of physiological and pathological cardiac hypertrophy
Nakamura, M., & Sadoshima, J. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0007-y · Cited by 1,709
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021884 · Cited by 1,003
Self-citationPhysiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 919
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 862
Shah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041886 · Cited by 436
Self-citationCellular and molecular pathobiology of heart failure with preserved ejection fraction
Mishra, S., & Kass, D. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00480-6 · Cited by 437
Self-citationGorter, T. M., van Veldhuisen, D. J., Bauersachs, J. K., Borlaug, B. A., Čelutkienė, J., Coats, A. J. S., Crespo-Leiro, M. G., Guazzi, M., Harjola, V., Heymans, S. R. B., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1029 · Cited by 402
Self-citationMolecular Physiology of Membrane Guanylyl Cyclase Receptors
Kühn, M. (2016) · Physiological Reviews · doi:10.1152/physrev.00022.2015 · Cited by 373
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 348
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
Solomon, S. D., Rizkala, A. R., Gong, J., Wang, W., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martínez, F. A., Packer, M., et al. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.04.013 · Cited by 317
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Dessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction
Heinzel, F. R., Hohendanner, F., Jin, G., Sedej, S., & Edelmann, F. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00374.2015 · Cited by 163
Kelly, M. P. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.11.004 · Cited by 152
Titin (TTN): from molecule to modifications, mechanics, and medical significance
Loescher, C. M., Hobbach, A. J., & Linke, W. A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab328 · Cited by 159
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Friebe, A., Sandner, P., & Schmidtko, A. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01779-z · Cited by 144
Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
D’Amario, D., Migliaro, S., Borovac, J. A., Restivo, A., Vergallo, R., Galli, M., Leone, A. M., Montone, R. A., Niccoli, G., Aspromonte, N., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01347 · Cited by 138
Liu, X., Xu, X. Y., Shang, R., & Chen, Y. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.06.004 · Cited by 134
PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress
Ranek, M. J., Kokkonen-Simon, K. M., Chen, A., Dunkerly-Eyring, B. L., Vera, M. P., Oeing, C. U., Patel, C. H., Nakamura, T., Zhu, G., Bedja, D., et al. (2019) · Nature · doi:10.1038/s41586-019-0895-y · Cited by 130
Self-citationVong, L. B., Bui, T. Q., Tomita, T., Sakamoto, H., Hiramatsu, Y., & Nagasaki, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.023 · Cited by 130
Panossian, A., Seo, E.-J., & Efferth, T. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.204 · Cited by 127
Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective
Bobin, P., Belacel-Ouari, M., Bedioune, I., Zhang, L., Leroy, J., Leblais, V., Fischmeister, R., & Vandecasteele, G. (2016) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2016.02.004 · Cited by 117
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
Sanders, O. D., & Rajagopal, L. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200191 · Cited by 117
Bullen, J. W., Tchernyshyov, I., Holewinski, R. J., Devine, L. R., Wu, F., Venkatraman, V., KASS, D., Cole, R. N., Eyk, J. E. V., & Semenza, G. L. (2016) · Science Signaling · doi:10.1126/scisignal.aaf0583 · Cited by 107
Self-citationCardiac Disorders and Pathophysiology of Sarcomeric Proteins
van der Velden, J., & Stienen, G. J. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00040.2017 · Cited by 117
What people with Down Syndrome can teach us about cardiopulmonary disease
Colvin, K. L., & Yeager, M. E. (2017) · European Respiratory Review · doi:10.1183/16000617.0098-2016 · Cited by 114
Proteomics Research in Cardiovascular Medicine and Biomarker Discovery
Lam, M. P. Y., Ping, P., & Murphy, E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.031 · Cited by 109
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
Kamel, R., Leroy, J., Vandecasteele, G., & Fischmeister, R. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00756-z · Cited by 100
Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases
Kokkonen-Simon, K. M., & Kass, D. A. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104756 · Cited by 101
Self-citationRecent Developments in Heart Failure
Dassanayaka, S., & Jones, S. P. (2015) · Circulation Research · doi:10.1161/circresaha.115.305765 · Cited by 103
Capillary leak and endothelial permeability in critically ill patients: a current overview
Saravi, B., Goebel, U., Hassenzahl, L. O., Jung, C., David, S., Feldheiser, A., Stopfkuchen-Evans, M. F., & Wollborn, J. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00582-8 · Cited by 112
The Microenvironment of the Pathogenesis of Cardiac Hypertrophy
Bazgir, F., Nau, J., Nakhaei‐Rad, S., Amin, E., Wolf, M. J., Saucerman, J. J., Lorenz, K., & Ahmadian, M. R. (2023) · Cells · doi:10.3390/cells12131780 · Cited by 106
Understanding heart failure with preserved ejection fraction: where are we today?
van Heerebeek, L., & Paulus, W. J. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0810-1 · Cited by 97
Self-citationChen, S., Zhang, Y., Lighthouse, J. K., Mickelsen, D. M., Wu, J., Yao, P., Small, E. M., & Chen, Y. (2019) · Circulation · doi:10.1161/circulationaha.119.042178 · Cited by 90
PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction
Knight, W. E., Chen, S., Zhang, Y., Oikawa, M., Wu, M., Zhou, Q., Miller, C. L., Cai, Y., Mickelsen, D. M., Moravec, C. S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607728113 · Cited by 88
Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology
Nagueh, S. F. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa228 · Cited by 96
Cyclic GMP and PKG Signaling in Heart Failure
Numata, G., & Takimoto, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.792798 · Cited by 97
Self-citationSkeletal muscle derived Musclin protects the heart during pathological overload
Szaroszyk, M., Kattih, B., Martín-Garrido, A., Trogisch, F. A., Dittrich, G. M., Grund, A., Abouissa, A., Derlin, K., Meier, M., Holler, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27634-5 · Cited by 86
Mongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 86
Zhazykbayeva, S., Pabel, S., Mügge, A., Sossalla, S. T., & Hamdani, N. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00742-0 · Cited by 91
Self-citationCardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
Kim, G. E., & Kass, D. A. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_82 · Cited by 79
Self-citationNatriuretic peptide pathways in heart failure: further therapeutic possibilities
Sangaralingham, S. J., Kühn, M., Cannone, V., Chen, H. H., & Burnett, J. C. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac125 · Cited by 87
Vettel, C., Lindner, M., Dewenter, M., Lorenz, K., Schanbacher, C., Riedel, M., Lämmle, S., Meinecke, S., Mason, F. E., Sossalla, S. T., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.310069 · Cited by 78
cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway
Park, M. S., Sandner, P., & Krieg, T. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-018-0679-9 · Cited by 75
Western Diet-Fed, Aortic-Banded Ossabaw Swine
Olver, T. D., Edwards, J. C., Jurrissen, T. J., Veteto, A. B., Jones, J. L., Gao, C., Rau, C., Warren, C. M., Klutho, P. J., Alex, L., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.004 · Cited by 74
Cardiac sarcomere mechanics in health and disease
Crocini, C., & Gotthardt, M. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00840-7 · Cited by 83
Buys, E. S., Zimmer, D. P., Chickering, J. G., Graul, R. M., Chien, Y., Profy, A. T., Hadcock, J. R., Masferrer, J. L., & Milne, G. T. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.05.009 · Cited by 75
Matsuo, A., Nagai‐Okatani, C., Nishigori, M., Kangawa, K., & Minamino, N. (2018) · Peptides · doi:10.1016/j.peptides.2018.08.006 · Cited by 73
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
Caturano, A., Vetrano, E., Galiero, R., Salvatore, T., Docimo, G., Epifani, R., Alfano, M., Sardu, C., Marfella, R., Rinaldi, L., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305165 · Cited by 77
TRPC Channels in Proteinuric Kidney Diseases
Hall, G., Wang, L., & Spurney, R. F. (2019) · Cells · doi:10.3390/cells9010044 · Cited by 70
Höllerhage, M., Moebius, C., Melms, J. C., Chiu, W., Goebel, J. N., Chakroun, T., Koeglsperger, T., Oertel, W. H., Rösler, T. W., Bickle, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11664-5 · Cited by 70
Pathophysiological insights into HFpEF from studies of human cardiac tissue
Fayyaz, A. U., Eltony, M., Prokop, L. J., Koepp, K. E., Borlaug, B. A., Dasari, S., Bois, M. C., Margulies, K. B., Maleszewski, J. J., Wang, Y., et al. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01067-1 · Cited by 75
Self-citationBaliga, R. S., Preedy, M. E. J., Dukinfield, M., Chu, S. M., Aubdool, A. A., Bubb, K. J., Moyes, A. J., Tones, M. A., & Hobbs, A. J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800996115 · Cited by 67
Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition
Hashimoto, T., Kim, G. E., Tunin, R. S., Adesiyun, T. A., Hsu, S., Nakagawa, R., Zhu, G., OʼBrien, J., Hendrick, J. P., Davis, R. E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030490 · Cited by 67
Self-citationNeuraminidase 1 is a driver of experimental cardiac hypertrophy
Chen, Q., Ma, G., Liu, J., Cai, Y., Zhang, J., Wei, T., Pan, A., Jiang, S., Xiao, Y., Xiao, P., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab347 · Cited by 66
Rainer, P. P., Dong, P., Sorge, M., Fert‐Bober, J., Holewinski, R. J., Wang, Y., Foss, C. A., An, S. S., Baracca, A., Solaini, G., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312082 · Cited by 67
Self-citationPosttranslational modifications of titin from cardiac muscle: how, where, and what for?
Koser, F., Loescher, C. M., & Linke, W. A. (2019) · FEBS Journal · doi:10.1111/febs.14854 · Cited by 67
The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies
Cai, Z., Wu, C., Xu, Y., Cai, J., Zhao, M., & Zu, L. (2022) · Aging and Disease · doi:10.14336/ad.2022.0523 · Cited by 69
Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G
Rainer, P. P., & Kass, D. A. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw107 · Cited by 63
Self-citationHFpEF, a Disease of the Vasculature: A Closer Look at the Other Half
Lyle, M. A., & Brozovich, F. V. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.001 · Cited by 63
Inflammatory Mechanisms in Heart Failure with Preserved Ejection Fraction
Daou, D., Gillette, T. G., & Hill, J. A. (2023) · Physiology · doi:10.1152/physiol.00004.2023 · Cited by 80
Effect of asymmetric dimethylarginine (ADMA) on heart failure development
Liu, X., Hou, L., Xu, D., Chen, A., Yang, L., Zhuang, Y., Xu, Y., Fassett, J. T., & Chen, Y. (2016) · Nitric Oxide · doi:10.1016/j.niox.2016.02.006 · Cited by 61
Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP
Subramanian, H., Froese, A., Jönsson, P., Schmidt, H., Gorelik, J., & Nikolaev, V. O. (2018) · Nature Communications · doi:10.1038/s41467-018-04891-5 · Cited by 61
cGMP Signaling and Modulation in Heart Failure
Blanton, R. M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000749 · Cited by 62
Chen, Y., Xu, M., Zhang, J., Ma, J., Gao, M., Zhang, Z., Xu, Y., & Liu, S. (2016) · Advanced Materials · doi:10.1002/adma.201604580 · Cited by 59
Roles of A-Kinase Anchoring Proteins and Phosphodiesterases in the Cardiovascular System
Ercu, M., & Klußmann, E. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5010014 · Cited by 59
Brescia, M., & Zaccolo, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101672 · Cited by 57
Shafiee-Nick, R., Afshari, A. R., Mousavi, S. H., Rafighdoust, A. A., Askari, V. R., Mollazadeh, H., Fanoudi, S., Mohtashami, E., Rahimi, V. B., Mohebbi, M., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.084 · Cited by 57
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
Petraina, A., Nogales, C., Krahn, T., Mucke, H. A., Lüscher, T. F., Fischmeister, R., Kass, D. A., Burnett, J. C. J., Hobbs, A. J., & Schmidt, H. H. H. W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab240 · Cited by 55
Self-citationNew Pharmacological Strategies to Increase cGMP
Buglioni, A., & Burnett, J. C. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-052914-091923 · Cited by 52
Kov́acs, Á., Alogna, A., Post, H., & Hamdani, N. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0814-x · Cited by 53
Self-citationNitric Oxide Nano-Delivery Systems for Cancer Therapeutics: Advances and Challenges
Vong, L. B., & Nagasaki, Y. (2020) · Antioxidants · doi:10.3390/antiox9090791 · Cited by 55
Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF
Agrawal, V., Kropski, J. A., Gokey, J. J., Kobeck, E., Murphy, M. B., Murray, K. T., Fortune, N. L., Moore, C. S., Meoli, D. F., Monahan, K., et al. (2023) · Circulation Research · doi:10.1161/circresaha.123.323119 · Cited by 52
Calamera, G., Moltzau, L. R., Levy, F. O., & Andressen, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042145 · Cited by 51
Ranek, M. J., Oeing, C. U., Sanchez‐Hodge, R., Kokkonen-Simon, K. M., Dillard, D., Aslam, M., Rainer, P. P., Mishra, S., Dunkerly-Eyring, B. L., Holewinski, R. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18980-x · Cited by 48
Self-citationMTORC1-Regulated Metabolism Controlled by TSC2 Limits Cardiac Reperfusion Injury
Oeing, C. U., Jun, S., Mishra, S., Dunkerly-Eyring, B. L., Chen, A., Martinez, M. I. G., Tahir, U. A., Gerszten, R. E., Paolocci, N., Ranek, M. J., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317710 · Cited by 51
Self-citationKolijn, D., Kov́acs, Á., Herwig, M., Lódi, M., Sieme, M., Haj, A. A., Sandner, P., Papp, Z., Reusch, H. P., Haldenwang, P. L., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00345 · Cited by 50
Self-citationLeveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction
Pinilla-Vera, M., Hahn, V. S., & Kass, D. A. (2019) · Circulation Research · doi:10.1161/circresaha.119.313682 · Cited by 52
Self-citationMoghtadaei, M., Polina, I. A., & Rose, R. A. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.12.001 · Cited by 48
Nitric oxide and pulmonary arterial hypertension
Chester, A. H., Yacoub, M. H., & Moncada, S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.14 · Cited by 51
PKG1α Cysteine-42 Redox State Controls mTORC1 Activation in Pathological Cardiac Hypertrophy
Oeing, C. U., Nakamura, T., Pan, S., Mishra, S., Dunkerly-Eyring, B. L., Kokkonen-Simon, K. M., Lin, B. L., Chen, A., Zhu, G., Bedja, D., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315714 · Cited by 49
Self-citationPrysyazhna, O. D., Burgoyne, J. R., Scotcher, J., Grover, S. P., Kass, D. A., & Eaton, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.724070 · Cited by 46
Self-citationMyocardial Phosphodiesterases and Their Role in cGMP Regulation
Dunkerly-Eyring, B. L., & Kass, D. A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000773 · Cited by 46
Self-citationInhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice
Mishra, S., Sadagopan, N., Sadagopan, N., Dunkerly-Eyring, B. L., Rodriguez, S., Sarver, D. C., Murphy, S. A., Knútsdóttir, H., Knútsdóttir, H., Jani, V., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148798 · Cited by 47
Self-citationMyocardial reverse remodeling: how far can we rewind?
Gonçalves‐Rodrigues, P., Leite-Moreira, A. F., & Falcão‐Pires, I. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00696.2015 · Cited by 48
Fert-Bober, J., Murray, C. I., Parker, S. J., & Van Eyk, J. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.310966 · Cited by 45
Molecular Screen Identifies Cardiac Myosin–Binding Protein-C as a Protein Kinase G-Iα Substrate
Thoonen, R., Giovanni, S., Govindan, S., Lee, D. I., Wang, G.-R., Calamaras, T. D., Takimoto, E., Kass, D. A., Sadayappan, S., & Blanton, R. M. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002308 · Cited by 45
Self-citationLi, J., Liu, C., Wei, N., Li, X., Liu, Y.-Y., Yang, R., & Jia, Y. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.011 · Cited by 45
From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
Franssen, C., Chen, H. S., Hamdani, N., & Paulus, W. J. (2015) · Heart · doi:10.1136/heartjnl-2015-307787 · Cited by 46
Self-citationPhosphodiesterase 9a Inhibition in Mouse Models of Diastolic Dysfunction
Methawasin, M., Strom, J. G., Borkowski, T., Hourani, Z., Runyan, R. B., Smith, J. E., & Granzier, H. L. M. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006609 · Cited by 44
Phosphodiesterase in heart and vessels: from physiology to diseases
Fu, Q., Wang, Y., Chen, Y., & Xiang, Y. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00015.2023 · Cited by 44
Pathophysiology of Aortic Valve Stenosis: Is It Both Fibrocalcific and Sex Specific?
Sritharen, Y., Enriquez-Sarano, M. L., Schaff, H. V., Casaclang‐Verzosa, G., & Miller, J. D. (2017) · Physiology · doi:10.1152/physiol.00025.2016 · Cited by 45
West, T. M., Wang, Q., Deng, B., Zhang, Y., Barbagallo, F., Reddy, G. R., Chen, D., Phan, K. S., Xu, B. Y., Isidori, A. M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012273 · Cited by 43
Lugnier, C., Meyer, A., Charloux, A., Andrès, E., Gény, B., & Talha, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101746 · Cited by 43
A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology
Hofmann, F. B. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-018-0690-1 · Cited by 43
Chen, S., Lv, L., Zhan, Z., Wang, X., You, Z., Luo, X., & You, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29382 · Cited by 42
Cardiac retinoic acid levels decline in heart failure
Yang, N., Parker, L. E., Yu, J., Jones, J. W., Liu, T., Papanicolaou, K. N., Talbot, C. C., Margulies, K. B., O'Rourke, B. P., Kane, M. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137593 · Cited by 42
Self-citationFRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons
Calamera, G., Li, D., Ulsund, A. H., Kim, J. J., Neely, O. C., Moltzau, L. R., Bjørnerem, M., Paterson, D. J., Kim, C., Levy, F. O., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0641-x · Cited by 42
Metadata
- Authors
- Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., Bedja, D., Kirk, J. A., Ranek, M. J., Dostmann, W. R., Kwon, C., Margulies, K. B., Van Eyk, J. E., Paulus, W. J., Takimoto, E., & Kass, D. A.
- Affiliations
- Johns Hopkins University (US)
- Tanabe Pharma Corporation (Japan) (JP)
- Amsterdam Cardiovascular Sciences (NL)
- Cedars-Sinai Medical Center (US)
- Kangwon National University (KR)
- University of Vermont (US)
- University of Pennsylvania (US)
- Corresponding author
- Kass, David A.
- ORCID
- Venue
- Nature
- Published
- 2015-03
- Volume
- 519
- Issue
- 7544
- Pages
- 472-476
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4376609
- OpenAlex
- W2020159180
- Cited by
- 353
- References
- 30
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 36 · 2023: 22 · 2022: 41 · 2021: 44 · 2020: 34 · 2019: 33 · 2018: 41 · 2017: 27 · 2016: 37 · 2015: 14
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- American Heart Association
- Pfizer
- University of Pennsylvania
- University of Connecticut
- Johns Hopkins University
- European Commission (261409)
- Fondation Leducq (HL-093432)
- Österreichischen Akademie der Wissenschaften
- National Institutes of Health (HHSN268201000032C, n01hv28180-13-0-0, HL-07227, HL089847)
- National Heart, Lung, and Blood Institute (NHLBI-HV-10-05, HL089297, R01HL093432, HL-07227, N01 HV028180, HHS-N268201000032C, R01HL119012, HL105993, HL093432, HL-119012, HL-68891, HL089847, P01HL107153, R01HL089297, R01HL089847, R01HL111198, R01HL105993, T32HL007227, R01HL068891)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PDE9A, PDE5A, cGMP signaling, cardiac hypertrophy, heart failure, pressure overload, cardiomyocytes, protein kinase G, heart disease treatment, nitric oxide synthase, neurohormones, cardiomyopathy
- MeSH terms
- Animals, Aortic Valve Stenosis, Cyclic GMP, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardium, Nitric Oxide, Phosphodiesterase Inhibitors, Pressure, Stress, Physiological, 3',5'-Cyclic-AMP Phosphodiesterases, Signal Transduction, Up-Regulation, Nitric Oxide Synthase, Muscle Cells, Natriuretic Peptides, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
